发明授权
US6063900A Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and
uses thereof
失效
分离的肿瘤排斥抗原前体MAGE-2衍生肽及其用途
- 专利标题： Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
- 专利标题（中）： 分离的肿瘤排斥抗原前体MAGE-2衍生肽及其用途
-
申请号： US667725申请日： 1996-06-21
-
公开(公告)号： US6063900A公开(公告)日： 2000-05-16
- 发明人: Cornelis J. M. Melief , Marjan J. W. Visseren , W. Martin Kast , Pierre van der Bruggen , Thierry Boon-Falleur
- 申请人： Cornelis J. M. Melief , Marjan J. W. Visseren , W. Martin Kast , Pierre van der Bruggen , Thierry Boon-Falleur
- 申请人地址： NY New York
- 专利权人： Ludwig Institute for Cancer Research
- 当前专利权人： Ludwig Institute for Cancer Research
- 当前专利权人地址： NY New York
- 主分类号： C12P21/08
- IPC分类号： C12P21/08 ; A61K35/26 ; A61K38/00 ; A61K38/04 ; A61K39/00 ; A61K39/395 ; A61P35/00 ; A61P37/00 ; C07K5/00 ; C07K7/06 ; C07K7/08 ; C07K14/47 ; C07K14/705 ; C07K14/74 ; C07K16/28 ; C12N5/00 ; A61K38/08 ; C12N5/06
摘要：
The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
公开/授权文献
- USD290288S Solar water tank heater 公开/授权日：1987-06-09
信息查询
